March, 10, 2017 - Medtronic announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved ...

To ensure imaging systems are operating safely and at optimum performance with appropriate and preventative maintenance, Toshiba Medical has introduced a customized PM Only Service Agreement to customers. The PM Only Service Agreement allows providers to fulfill and document that they are compliant with the Centers for Medicare & Medicaid (CMS) Directive and The Joint Commission’s (TJC) guidelines of ensuring all imaging equipment meets manufacturers’ specifications.

Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral arterial disease (PAD). This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigational device, which uses Medtronic’s IN.PACT Admiral drug coating technology.

March 9, 2017 — Boston Scientific announced the German District Court of Düsseldorf has determined that Edwards ...

Through computed tomography (CT) images of the heart and other types of imaging, build-up of dangerous coronary plaques — which restrict the flow of blood to the heart — can be detected, even before a person develops symptoms of heart disease. Because of this, there is increasing interest in using these imaging techniques to screen for heart disease. According to a review published recently in JACC: Cardiovascular Imaging, a simple CT imaging technique called a coronary artery calcium (CAC) scan — often referred to as a calcium scan—may be particularly useful when screening for coronary artery disease.

Despite global political uncertainties and a sluggish economic outlook for 2017, the global healthcare industry is set for an invigorating year, according to a new analysis from Frost & Sullivan. This outlook is due to a partial realization of major healthcare policies and initiatives, technology advancements and value-based care driving the adoption and need for consumer-centric targeted therapies. Future drugs and medical devices will be more targeted to meet the unique needs of emerging markets (e.g. China, India, Brazil) which demonstrate high growth opportunities compared developed markets (e.g., the United States and Western Europe. Growing at a CAGR of 4.8 percent, the industry is likely to reach revenue of $1,731.8 billion.